DK0923370T3 - Acetylcholinesteraseinhibitorer til behandling og diagnosticering af sövnrelaterede respirationsforstyrrelser - Google Patents

Acetylcholinesteraseinhibitorer til behandling og diagnosticering af sövnrelaterede respirationsforstyrrelser

Info

Publication number
DK0923370T3
DK0923370T3 DK96943443T DK96943443T DK0923370T3 DK 0923370 T3 DK0923370 T3 DK 0923370T3 DK 96943443 T DK96943443 T DK 96943443T DK 96943443 T DK96943443 T DK 96943443T DK 0923370 T3 DK0923370 T3 DK 0923370T3
Authority
DK
Denmark
Prior art keywords
sleep
pct
diagnosis
treatment
respiratory disorders
Prior art date
Application number
DK96943443T
Other languages
Danish (da)
English (en)
Inventor
Jan Hedner
Original Assignee
Pharmapnea Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmapnea Ab filed Critical Pharmapnea Ab
Application granted granted Critical
Publication of DK0923370T3 publication Critical patent/DK0923370T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Radiation-Therapy Devices (AREA)
DK96943443T 1995-12-19 1996-12-17 Acetylcholinesteraseinhibitorer til behandling og diagnosticering af sövnrelaterede respirationsforstyrrelser DK0923370T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9504537A SE9504537D0 (sv) 1995-12-19 1995-12-19 Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet

Publications (1)

Publication Number Publication Date
DK0923370T3 true DK0923370T3 (da) 2006-03-27

Family

ID=20400641

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96943443T DK0923370T3 (da) 1995-12-19 1996-12-17 Acetylcholinesteraseinhibitorer til behandling og diagnosticering af sövnrelaterede respirationsforstyrrelser

Country Status (11)

Country Link
US (1) US6034117A (fr)
EP (1) EP0923370B1 (fr)
JP (1) JP3756193B2 (fr)
AT (1) ATE309795T1 (fr)
AU (1) AU701911B2 (fr)
CA (1) CA2240717C (fr)
DE (1) DE69635459T2 (fr)
DK (1) DK0923370T3 (fr)
ES (1) ES2256865T3 (fr)
SE (1) SE9504537D0 (fr)
WO (1) WO1997022339A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001522891A (ja) * 1997-11-14 2001-11-20 アクゾ・ノベル・エヌ・ベー 睡眠時無呼吸を治療するためのミルタザピンの使用
US6352715B1 (en) * 1998-02-19 2002-03-05 Sagittarius Life Science Corp Transdermal rate-controlled delivery of Huperzine A for treatment of alzheimer's disease
US6262081B1 (en) * 1998-07-10 2001-07-17 Dupont Pharmaceuticals Company Composition for and method of treating neurological disorders
DE19856897A1 (de) * 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen
AU775914B2 (en) * 1998-12-24 2004-08-19 Janssen Pharmaceutica N.V. Controlled release galantamine composition
DE10004790B4 (de) * 2000-02-01 2004-09-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung von Zaleplon, Verfahren zu seiner Herstellung und seine Verwendung
US20070173893A1 (en) * 2000-10-20 2007-07-26 Pitts Walter C Method and apparatus for preventing obstructive sleep apnea
FR2820423B1 (fr) * 2001-02-05 2005-12-02 Assist Publ Hopitaux De Paris Tartrate et phosphate de 3,4-diaminopyridine, compositions pharmaceutiques et utilisations
CN1194688C (zh) * 2001-07-03 2005-03-30 山东绿叶制药股份有限公司 石杉碱甲及其衍生物或其盐的注射用缓释微球及其制备方法
US20030225031A1 (en) * 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
AU2003287433A1 (en) * 2002-11-01 2004-06-07 Oregon Health And Science University Treatment of hyperkinetic movement disorder with donepezil
US20040266659A1 (en) * 2003-06-27 2004-12-30 Stephen LaBerge Substances that enhance recall and lucidity during dreaming
US7297691B2 (en) 2003-08-13 2007-11-20 Janssen Pharmaceutica N.V. Treatment of sleep disorders with cholinesterase inhibitors
US7795307B2 (en) 2003-10-21 2010-09-14 Colucid Pharmaceuticals, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
DE10354894A1 (de) * 2003-11-24 2005-07-07 Hf Arzneimittelforschung Gmbh Orale Formulierungen des Desoxypeganins und deren Anwendungen
US7984714B2 (en) 2006-09-29 2011-07-26 Nellcor Puritan Bennett Llc Managing obstructive sleep apnea and/or snoring using local time released agents
JP2010518010A (ja) 2007-02-02 2010-05-27 コルシド・ファーマシューティカルズ・インコーポレイテッド コリンエステラーゼを阻害する化合物
AU2008276459A1 (en) * 2007-07-18 2009-01-22 Colucid Pharmaceuticals, Inc. Methods for promoting wakefulness
EP2251010A1 (fr) 2009-05-08 2010-11-17 Sygnis Bioscience GmbH & Co. KG Utilisation de tiabendazole et dérivés correspondants pour la thérapie de conditions neurologiques
JP2014503593A (ja) * 2011-01-28 2014-02-13 ファンタスティック・メディカル・リサーチ・インスティテュート・エルエルシー 閉塞性睡眠時無呼吸を処置するための方法
US9642841B1 (en) 2014-03-14 2017-05-09 James M. Hand Snoring treatment
JP6526475B2 (ja) * 2015-04-30 2019-06-05 サンスター株式会社 経皮唾液腺投与用の唾液分泌促進剤
US10617694B2 (en) * 2016-05-11 2020-04-14 Jan Hedner Sultiame for the treatment of sleep apnea

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4278679A (en) * 1980-05-01 1981-07-14 Chromalloy American Corporation Combination of two or more drugs in a single dosage form wherein one of the drugs is a physostigmine compound
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
DE4115558A1 (de) * 1991-05-13 1992-11-19 Dresden Arzneimittel Prophylaktisches antidot gegen phosphororganische gifte
WO1992020327A1 (fr) * 1991-05-14 1992-11-26 Ernir Snorrason Traitement des etats de fatigue a l'aide d'inhibiteurs de cholinesterase
DE19548812A1 (de) * 1995-12-27 1997-07-03 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation

Also Published As

Publication number Publication date
DE69635459T2 (de) 2006-08-03
AU701911B2 (en) 1999-02-11
CA2240717A1 (fr) 1997-06-26
DE69635459D1 (de) 2005-12-22
AU1217697A (en) 1997-07-14
CA2240717C (fr) 2002-11-26
EP0923370B1 (fr) 2005-11-16
ES2256865T3 (es) 2006-07-16
ATE309795T1 (de) 2005-12-15
SE9504537D0 (sv) 1995-12-19
US6034117A (en) 2000-03-07
JP3756193B2 (ja) 2006-03-15
WO1997022339A1 (fr) 1997-06-26
EP0923370A2 (fr) 1999-06-23
JP2000511873A (ja) 2000-09-12

Similar Documents

Publication Publication Date Title
DK0923370T3 (da) Acetylcholinesteraseinhibitorer til behandling og diagnosticering af sövnrelaterede respirationsforstyrrelser
DK0728006T3 (da) Anvendelse af mannosephosphater til behandlingen af fibrotiske lidelser
BR9406941A (pt) Formulação oral com revestimento entèrico processo para a preparação da formulação processo para a inibição da secreção de acido gástrico em mamiferos e no homem e processo para o tratamento de doencas relacionados ao ácidos gástrico em mamiferos e no homem
ATE217197T1 (de) Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa
DE69616333D1 (de) Thip zur behandlung von schlafstörungen
NO20083958L (no) Prodrugs av GABA-analoger, sammensetninger og anvendelse derav
DK1066036T3 (da) Midler med serotoninrelateret aktivitet til behandling af sövnapnö
IL165255A0 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for teh treatment of alzheimer's disease
DK0758241T3 (da) Anvendelse af visse methanbisphosphonsyrederivater til at hindre løsning og vandring af proteser
DE59401401D1 (de) Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit
ATE252897T1 (de) Verwendung von p-aminophenolderivaten zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von neurodegenerativen erkrankungen
DK0846173T3 (da) Anvendelse af et anti-interleukin-9-antistof til fremstilling af et lægemiddel til behandling af astma
DK0866711T3 (da) Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö
JO3446B1 (ar) طريقة لمعالجة الأرق الأولي
DE69924146D1 (de) Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen
BG104654A (en) Method for treatment of chronic obstructive pulmonary disease (copd)
DE69525631D1 (de) Verwendung von prostaglandinen zur herstellung eines arzneimittels zur prävention und behandlung des sekundären katarakts
SE9801368D0 (sv) New use
MA27157A1 (fr) Methode de traitement d'affections osseuses.
ES2137665T3 (es) Nuevos derivados de piridina o piridazina, procedimientos para su preparacion, y medicamentos que contienen estos compuestos.
MY124089A (en) Use of cetirizine for preventing the onset of asthma
DK1105132T3 (da) Anvendelse af R(+)-G(A)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorphenyl)ethyl]-4-piperidinemethanol til behandling af obstruktiv søvnapnø
EE9700327A (et) Meetod anhüdroekgoniini estrite valmistamiseks
JO2127B1 (en) How to prevent asthma